Stability-indicating methods for the determination of olanzapine in presence of its degradation products
Open Access
- 30 June 2014
- journal article
- Published by European Journal of Chemistry in European Journal of Chemistry
- Vol. 5 (2), 311-320
- https://doi.org/10.5155/eurjchem.5.2.311-320.951
Abstract
Simple, sensitive and precise spectrophotometric and chemometric stability indicating techniques were adopted for Olanzapine (OLA) determination in presence of its degradation products over a concentration range of 0.002-0.02 mg/mL. The spectrophotometric technique involves six methods; first method is first derivative (D1) spectrophotometric one, which allows the determination of OLA in presence of its acidic and alkaline degradation products at 261.2 and 260.6 nm with mean percentage recoveries of 99.90±0.48 and 99.95±0.67, respectively. While second derivative spectrophotometry (D2) was used for determination of drug in presence of alkaline degradation products. Second method is first-derivative of the ratio spectra (DR1) for determination of OLA in presence of its acidic and alkaline degradation products at 267.9 and 251.6 nm, respectively with mean percentage recoveries of 99.81±0.64 and 100.53±1.11, respectively. The third method is pH-induced difference method for determination of OLA in presence of its acidic and alkaline degradation products; with mean percentage recoveries 100.09±0.06 and 99.77±0.78, respectively. Fourth method is the Q-analysis (absorption ratio) method, which involves the formation of absorbance equation at 296.3 nm (isosbestic point) and 271 nm (λmax of OLA) for the determination of OLA in presence of its acidic degradation products. The mean percentage recovery is 100.07±1.51. Fifth method based on dual wavelength selection was developed for the determination of OLA in presence of its acidic degradation products with mean percentage recovery of 100.36±0.69. Sixth method based on simple mathematic algorithm by the bivariate calibration was also used for the determination of OLA with the mean percentage recovery of 101.72±1.10. The second technique is chemometrics, which includes determination of OLA in presence of its acidic degradation products using multivariate calibration methods (the classical least squares (CLS), principle component regression (PCR) and partial least squares (PLS)) using the information contained in the absorption spectra.Keywords
This publication has 41 references indexed in Scilit:
- Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluidJournal of Pharmaceutical and Biomedical Analysis, 2010
- Change in the spectral characteristics of olanzapine upon protonationDoklady Chemistry, 2010
- Highly sensitive spectrophotometric determination of olanzapine using cerium(IV) and iron(II) complexes of 1,10-phenanthroline and 2,2′-bipyridylJournal of Analytical Chemistry, 2010
- Simultaneous RP-HPLC and HPTLC estimation of fluoxetine hydrochloride and olanzapine in tablet dosage formsIndian Journal of Pharmaceutical Sciences, 2009
- Stability-indicating simultaneous HPTLC method for olanzapine and fluoxetine in combined tablet dosage formIndian Journal of Pharmaceutical Sciences, 2008
- Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MSJournal of Separation Science, 2007
- Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissueJournal of Chromatography B, 2007
- Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detectionJournal of Chromatography B, 2007
- Batch and flow-injection methods for the spectrophotometric determination of olanzapineAnalytica Chimica Acta, 2004
- Application of the bivariate spectrophotometric method for the determination of metronidazole, furazolidone and di-iodohydroxyquinoline in pharmaceutical formulationsJournal of Pharmaceutical and Biomedical Analysis, 1997